Wedbush Issues Optimistic Estimate for ZNTL Earnings

Key Points

• Analysts at Wedbush have increased their Q3 2025 earnings estimates for Zentalis Pharmaceuticals to ($0.47) EPS, while maintaining a "Neutral" rating and a price target of $4.00.
• Institutional investors have significantly increased their stakes in Zentalis, with Millennium Management boosting its holdings by over 220% in the first quarter of 2023.
• The average rating for Zentalis Pharmaceuticals is currently at "Moderate Buy", with a consensus target price of $8.20 set by investment analysts.

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) - Equities researchers at Wedbush lifted their Q3 2025 earnings estimates for Zentalis Pharmaceuticals in a research report issued to clients and investors on Wednesday, August 6th. Wedbush analyst R. Driscoll now forecasts that the company will earn ($0.47) per share for the quarter, up from their previous forecast of ($0.58). Wedbush currently has a "Neutral" rating and a $4.00 target price on the stock. The consensus estimate for Zentalis Pharmaceuticals' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Zentalis Pharmaceuticals' Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.81) EPS, FY2026 earnings at ($1.41) EPS, FY2027 earnings at ($1.14) EPS, FY2028 earnings at ($0.51) EPS and FY2029 earnings at ($0.01) EPS.

Other equities research analysts have also recently issued reports about the stock. Wells Fargo & Company reduced their price target on shares of Zentalis Pharmaceuticals from $6.00 to $5.00 and set an "equal weight" rating for the company in a report on Thursday, August 7th. HC Wainwright upgraded shares of Zentalis Pharmaceuticals to a "strong-buy" rating in a report on Thursday, August 7th. Finally, Wall Street Zen raised shares of Zentalis Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. Four analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.20.

Zentalis Pharmaceuticals Stock Up 0.3%

NASDAQ:ZNTL traded up $0.01 during trading hours on Monday, reaching $1.50. The company had a trading volume of 334,757 shares, compared to its average volume of 1,232,247. The firm has a market cap of $107.84 million, a price-to-earnings ratio of -0.66 and a beta of 1.71. The business's 50-day simple moving average is $1.38 and its two-hundred day simple moving average is $1.54. Zentalis Pharmaceuticals has a twelve month low of $1.01 and a twelve month high of $5.44.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.19.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in ZNTL. Raymond James Financial Inc. bought a new position in shares of Zentalis Pharmaceuticals during the fourth quarter valued at about $68,000. JPMorgan Chase & Co. raised its position in Zentalis Pharmaceuticals by 75.7% in the fourth quarter. JPMorgan Chase & Co. now owns 859,710 shares of the company's stock worth $2,605,000 after acquiring an additional 370,511 shares during the period. Franklin Resources Inc. bought a new stake in Zentalis Pharmaceuticals in the fourth quarter worth about $323,000. Geode Capital Management LLC raised its position in Zentalis Pharmaceuticals by 1.6% in the fourth quarter. Geode Capital Management LLC now owns 1,312,964 shares of the company's stock worth $3,979,000 after acquiring an additional 20,864 shares during the period. Finally, Wells Fargo & Company MN raised its position in Zentalis Pharmaceuticals by 26.8% in the fourth quarter. Wells Fargo & Company MN now owns 34,609 shares of the company's stock worth $105,000 after acquiring an additional 7,305 shares during the period.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.